Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
This study has been completed.
Study NCT00058487 Information provided by National Cancer Institute (NCI)
First Received: April 7, 2003 Last Updated: July 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Liver Cancer
Additional conditions recognized in this trial
Carcinoma, Hepatocellular
Liver Neoplasms
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
epirubicin hydrochloride
thalidomide
Additional drug interventions recognized in this trial
Epirubicin
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Back to top of Main Content
